title: Scheie syndrome: enzyme replacement therapy does not prevent progression of cervical myelopathy due to spinal cord compression.
abstract: Hurler-Scheie syndrome is caused by alpha-l-iduronidase deficiency. Enzyme replacement therapy (ERT) can improve physical capacity and reduces organomegaly. However, the effect on bradytrophic connective tissue is limited. As intravenously administered enzyme cannot cross the blood-brain barrier, the therapy of choice for the more severe Hurler syndrome is haematopoietic stem cell transplantation (HCT). In the more attenuated Scheie syndrome, neurological impairment is less severe; therefore, ERT may be appropriate to treat these patients. Information on long-term outcome in Scheie patients undergoing ERT is scarce. We report a 38-year-old female Scheie patient who has been on ERT for 8 years. While non-neurological symptoms improved, she developed paresthesias in her hands and feet and progressive pain in her legs. Somatosensory evoked potentials were abnormal, suggesting dysfunction of the dorsal funiculus and lemniscus medialis. After 6 years of ERT, a spinal MRI showed dural thickening at the upper cervical spine. These soft-tissue deposits are presumably due to the accumulation of mucopolysaccharides. Intramedullary hyperintensities at the level of C1/2 revealed cervical myelopathy. An MRI before the start of ERT had shown milder spinal lesions. Cystic lesions in the white matter of the centrum semiovale due to dilated Virchow-Robin spaces were essentially unchanged compared with the MRI scan before ERT. Decompression of the spinal cord resulted in clinical improvement. In an adult patient with Scheie syndrome, ERT failed to prevent progression of cervical myelopathy. Clinical significance of cerebral changes is unclear. Whether early HCT or intrathecal ERT could have prevented these lesions remains speculative.
authors.affiliation: Department of Paediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany. Illsinger.Sabine@mh-hannover.de
authors.forename: S
authors.initials: S
authors.lastname: Illsinger
authors.forename: T
authors.initials: T
authors.lastname: Lücke
authors.forename: H
authors.initials: H
authors.lastname: Hartmann
authors.forename: E
authors.initials: E
authors.lastname: Mengel
authors.forename: W
authors.initials: W
authors.lastname: Müller-Forell
authors.forename: F
authors.initials: F
authors.lastname: Donnerstag
authors.forename: A M
authors.initials: AM
authors.lastname: Das
mesh_terms: D000328:Adult; D001921:Brain / Q000473:pathology; D002574:Cervical Vertebrae; D018450:Disease Progression; D056947:Enzyme Replacement Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007068:Iduronidase / Q000627:therapeutic use*; D008059:Mucopolysaccharidosis I / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D013117:Spinal Cord Compression / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology
chemical_list: D007068:Iduronidase